Article Text
PDF
Abstract
Background Hearing loss has been proposed as a modifiable risk factor for dementia. However, the relationship between hearing, neurodegeneration, and cognitive change, and the extent to which pathological processes such as Alzheimer’s disease and cerebrovascular disease influence these relationships, is unclear.
Methods Data from 287 adults born in the same week of 1946 who underwent baseline pure tone audiometry (mean age=70.6 years) and two time point cognitive assessment/multimodal brain imaging (mean interval 2.4 years) were analysed. Hearing impairment at baseline was defined as a pure tone average of greater than 25 decibels in the best hearing ear. Rates of change for whole brain, hippocampal and ventricle volume were estimated from structural MRI using the Boundary Shift Integral. Cognition was assessed using the Pre-clinical Alzheimer’s Cognitive Composite. Regression models were performed to evaluate how baseline hearing impairment associated with subsequent brain atrophy and cognitive decline after adjustment for a range of confounders including baseline β-amyloid deposition and white matter hyperintensity volume.
Results 111 out of 287 participants had hearing impairment. Compared with those with preserved hearing, hearing impaired individuals had faster rates of whole brain atrophy, and worse hearing (higher pure tone average) predicted faster rates of hippocampal atrophy. In participants with hearing impairment, faster rates of whole brain atrophy predicted greater cognitive change. All observed relationships were independent of β-amyloid deposition and white matter hyperintensity volume.
Conclusions Hearing loss may influence dementia risk via pathways distinct from those typically implicated in Alzheimer’s and cerebrovascular disease in cognitively unimpaired older adults.
- ALZHEIMER'S DISEASE
- AMYLOID
- CEREBROVASCULAR DISEASE
- COGNITIVE NEUROPSYCHOLOGY
- DEMENTIA
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
Introduction
Hearing loss has been proposed as a risk factor for dementia.1–4 However, the mechanisms by which hearing loss may influence neurodegeneration and cognitive decline are uncertain. In cross-sectional analyses, we have previously shown that peripheral hearing ability measured with pure tone audiometry did not predict β-amyloid (Aβ) deposition, white matter hyperintensity volume (WMHV) or Alzheimer’s disease-pattern neurodegeneration in adults aged approximately 70 years born in the same week of 1946.5 Building on this work, we used longitudinal data from the same cohort to investigate how hearing ability, Aβ-deposition and WMHV influence subsequent change in cognitive performance and brain atrophy.
Methods
Participants
We included data from 287 participants born in the same week of 1946 who underwent two time point cognitive assessment/multimodal brain imaging (mean age at baseline 70.5 years, mean interval between assessments 2.4 years) as part of Insight-46, a substudy of the MRC National Survey of Health and Development.6
Exclusions from the original Insight 46 sample (n=502) included no baseline imaging (n=31); baseline imaging quality control failure (n=15); pre-existing diagnosis of mild cognitive impairment, dementia or major neurological disorder (n=48); confounding otological pathology (n=16); hearing testing equipment unavailable (n=19); missing APOE genotype (n=2); missing socioeconomic position data (n=3) and no longitudinal follow-up visit data (n=81).
Hearing assessment
Baseline hearing assessment included obtaining audiometric thresholds for each ear at 0.5, 1, 2 and 4 kHz using calibrated Maico-MA-25 audiometers with sound-excluding TDH-49 earphones in audiocups. Pure-tone averages (PTAs) in the better hearing ear were calculated using thresholds for 0.5, 1, 2 and 4 kHz.5 Hearing impairment was defined as a PTA greater or equal to 25 dB HL.
Imaging analysis
Florbetapir PET and MRI data were acquired on a Single Siemens Biograph 3-Tesla PET/MRI scanner. Aβ-status (negative/positive) at baseline was determined using previously published methodology.5 7 WMHV was estimated using BaMoS.8 Total intracranial volume (TIV) was calculated using Statistical Parametric Mapping 12. Changes in whole-brain, ventricular and hippocampal volume were calculated from baseline and repeat 3D T1-weighted MRI with the boundary shift integral (BSI).7 9
Cognitive testing
Cognition was assessed using an adapted version of the Preclinical Alzheimer’s Cognitive Composite (PACC), composed of the following tests: Mini-Mental State Examination, Logical Memory IIa from the Wechsler Memory Scale-Revised, Digit-Symbol Substitution test from the Wechsler Adult Intelligence Scale-Revised and the 12-item Face-Name test.10
Statistical analysis
Wilcoxon rank sum tests, t-tests and Fisher’s exact test were used to assess unadjusted associations between demographic variables and hearing impairment (table 1).
Relationship between peripheral hearing ability and baseline demographics
Area under the curve (AUC) analyses were performed to investigate whether hearing impairment or PTA predicted baseline Aβ-status. Generalised linear models using the gamma distribution and log link were used to investigate whether PTA predicted baseline WMHV, as per previous work.5
Linear regression models were used to test associations between baseline peripheral hearing ability and longitudinal measurements of brain volume (whole brain, total hippocampal atrophy and ventricular expansion) and cognitive performance following adjustment for baseline Aβ-deposition, baseline WMHV, age, sex, APOE genotype, education, childhood cognition and socioeconomic position. For BSI analyses, TIV was included as a covariate. To investigate if associations between hearing and atrophy (BSI) relate to Alzheimer’s or cerebrovascular disease, we assessed interactions with Aβ-deposition and baseline WMHV. We additionally assessed if relationships between atrophy (BSI) and rates of cognitive decline (change in PACC) were influenced by hearing.
Results were expressed using a standard statistical threshold of <0.05, as well as a more conservative Bonferroni-corrected threshold of p<0.0125, based on the four primary outcomes of interest.
Results
111 out of 287 participants had evidence of hearing impairment. Relationships between hearing and demographic variables are detailed in table 1.
As per cross-sectional analysis,5 there was no evidence that hearing ability independently predicted Aβ-status or WMHV at baseline in this longitudinal sample. In this longitudinal sample 22/176 participants with normal peripheral hearing and 26/111 hearing impaired participants were classified as amyloid positive (mean Standardized uptake value (SUVR) 0.55 and 0.57, respectively, using an eroded subcortical white matter reference region). A base model combining age, sex, WMHV, education, childhood cognition, socioeconomic position and APOE genotype, provided an AUC for Aβ-positivity of 0.73 (95% CI 0.66 to 0.81) and predictive ability was not significantly improved by inclusion of hearing impairment (AUC 0.76, 95% CI 0.69 to 0.83) or PTA (AUC 0.75, 95% CI 0.68 to 0.82). After adjustment for age, sex, Aβ-status, education, childhood cognition, socioeconomic position and APOE the ratio of mean WMHV for hearing impaired: not hearing impaired was 0.83 (95% CI 0.62 to 1.10 p=0.2) and the proportional change in mean WMHV for each dB HL increase in PTA was 0.99 (95% CI 0.98 to 1.00, p=0.5).
Compared with those with preserved hearing, there was evidence that hearing impaired individuals had faster rates of whole brain atrophy (p=0.031) (table 2 and figure 1A). There was evidence that higher PTA (worse hearing) also predicted faster rates of hippocampal atrophy (p=0.023) (table 2 and figure 1B). These results were not significant using a Bonferroni-based statistical threshold, but all longitudinal volume results were directionally consistent with each other making it less likely these were a consequence of a type I error. There was no evidence that hearing ability predicted change in PACC score (table 2). These effects remained after adjustment for Aβ-status and WMHV. Furthermore, there was no evidence of an interaction between hearing ability and Aβ-status or WMHV in terms of their effects on atrophy or cognitive change.
(A) Relationship between hearing impairment and whole brain atrophy rates. (B) Relationship between pure tone average and hippocampal atrophy rates. (C) Relationship between change in cognitive performance and whole brain atrophy in participants with normal hearing. (D) Relationship between change in cognitive performance and whole brain atrophy in participants in participants with peripheral hearing impairment. Scatter plots show the raw data. The solid line represents the marginal adjusted mean following regression modelling (adjusted for baseline amyloid deposition, baseline white matter hyperintensity volume, age, sex, APOE genotype, educational attainment, childhood cognitive ability, socioeconomic position and total intracranial volume). The dashed lines represent the 95% CIs. Negative volume change values correspond to increased rates of brain atrophy. *p<0.05; **p<0.0125 (Bonferroni threshold). PACC, Preclinical Alzheimer’s Cognitive Composite.
Linear regression models testing associations between baseline hearing ability and cross-sectional/longitudinal measurements of brain volume (whole brain, total hippocampal and ventricular), and the Preclinical Alzheimer’s Cognitive Composite following adjustment for amyloid deposition, white matter hyperintensity volume, age, sex, APOE genotype, educational attainment, childhood cognitive ability, socioeconomic position and total intracranial volume (for volumetric brain analyses only)
There was evidence of an interaction between hearing impairment and the relationship between whole brain atrophy and cognitive change (p=0.031): while there was no evidence of an association between rates of brain atrophy and cognitive change in participants with preserved hearing (β-coefficient=0.002, p=0.68, figure 1C), in those with hearing impairment faster rates of whole brain atrophy predicted greater cognitive change (β-coefficient=0.017, p=0.004, figure 1D). Again, all observed relationships were independent of Aβ-status and WMHV. This relationship remained evident following removal of an outlier with BSI less than −15 mL per year (β-coefficient=0.012, p=0.042).
Discussion
We demonstrate that peripheral hearing impairment predicts faster rates of brain atrophy in older adults. This is consistent with previous reports,11 12 but extends these findings to show these effects are independent of Aβ-status and WMHV suggesting that relationships between hearing loss and neurodegeneration may be driven by mechanisms other than Alzheimer’s or cerebrovascular disease.7 This does not, however, preclude the possibility that accelerated atrophy involving key structures such as the hippocampus could prime or accelerate the subsequent emergence of neurodegenerative pathologies such as Alzheimer’s disease.2
Hearing impairment did not predict cognitive change in those with normal hearing, but faster rates of whole brain atrophy did predict greater cognitive change in participants with hearing impairment. Hearing loss imposes a cognitive load, particularly on processes that require speech comprehension: our findings suggest that this may cause cognitive dysfunction to become manifest, in situations where brain reserve is already limited (e.g. due to increased underlying brain atrophy).13 Future work examining the precise mechanisms that predict cognitive change in the context of hearing impairment are required. In particular, investigating to what extent auditory impairment is a risk factor for, or manifestation of neurodegenerative processes, and whether these can be mitigated by appropriate hearing interventions.4 14
It is important to note that the effects of peripheral hearing ability on atrophy rates and cognition in this sample of cognitively healthy older adults were subtle and the clinical meaningfulness of these effects is uncertain. Longer-term follow-up looking at data such as conversion to dementia will be vital to establish the true relevance of this finding.
This study benefits from detailed longitudinal phenotyping as well as a unique level of age-matching. Limitations include the fact that some of the cognitive tests have an auditory component, reduced sample size and a relatively selective population due to participant drop-out, as well as relatively short duration of follow-up.15 Future work with larger sample sizes, longer follow-up durations and more detailed biomarker characterisation will be of value. In addition, this study does not investigate central auditory processing, a cognitively demanding process involving a range of brain areas, which has been shown to have particular relevance in neurodegenerative conditions and should be an important focus for future work.16
Our data suggest a complex interplay of hearing ability, neurodegeneration and cognition and implicate pathways separate to those typically implicated in Alzheimer’s and cerebrovascular disease.
Ethics statements
Patient consent for publication
Ethics approval
This study involves human participants and ethical approval was granted by National Research Ethics Service Committee London (reference 14/LO/1173). Participants gave informed consent to participate in the study before taking part.
Acknowledgments
The authors are very grateful to the study participants for their contributions to Insight 46 and for their commitment to research over the past 7 decades. They are grateful to the radiographers and nuclear medicine physicians at the University College London Institute of Nuclear Medicine; the staff at the Leonard Wolfson Experimental Neurology Centre and the Bloomsbury Centre for Clinical Phenotyping at UCL; neuroradiologists Dr Chandrashekar Hoskote, Dr Sachit Shah and Professor Frederik Barkhof for providing clinical reads for the MRI scans; the Dementia Research Centre trials team for assistance with imaging quality control; Dan Marcus and Rick Herrick for assistance with XNAT; the Insight 46 data collection team including: Dr Chris Lane, Dr Ashvini Keshavan; Dr Sarah Buchanan; Dr Matthew Harris; Dr Aaron Wagen; and Dr Mathew Storey, Miss Heidi Murray-Smith and Dr Philip Curran for assistance with data sharing with the MRC Unit for Lifelong Health and Ageing. They are also particularly indebted to the support of the late Chris Clark of Avid Radiopharmaceuticals who championed this study from its outset.
Footnotes
X @cjdhardy, @davecash75, @jmschott
Contributors TDP, CH, JDW, MR, NCF and JMS conceived the study. JMN provided statistical support. DC, WC, CS assisted with imaging processing. KL and S-NJ assisted with collation of cognitive data. TDP, CH, SK, JMN and JMS interpreted the data. TDP drafted the initial manuscript. All authors contributed to revision and editing of the manuscript.
Funding Insight 46 is funded by grants from Alzheimer's Research UK (ARUK-PG2014-1946, ARUK-PG2017-1946 principal investigators (PIs) JMS, NCF, MR), Alzheimer's Association (SG-666374-UK BIRTH COHORT PI JMS), the Medical Research Council Dementias Platform UK (CSUB19166 PIs JMS, NCF, MR), The Wolfson Foundation (PR/ylr/18575 PIs NCF, JMS), The Medical Research Council (MC-UU-12019/1 PI MR MC-UU-12019/3 PI MR), Selfridges Group Foundation (22/3/18 PIs JMS) and Brain Research Trust (UCC14191, PI JMS). TP has received support from a Wellcome Trust Clinical Research Fellowship (Clinical Research Fellowship 200109/Z/15/Z TP) and a UK National Institute of Health and Care Research academic clinical lectureship. CH was supported by a Royal National Institute for Deaf People and Dunhill Medical Trust Pauline Ashley Fellowship (PA23). SK and WC report no disclosures relevant to the manuscript. DMC was supported by Alzheimer's Research UK (ARUK-PG2017-1946), the UCL/UCLH National Institute of Health and Care Research Biomedical Research Centre, and the UK Dementia Research Institute, which is funded by the UK Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research UK. JMN reports no disclosures relevant to the manuscript. CS was supported by the Alzheimer's Society Junior Fellowship (AS-JF-17–011) and is a scientific advisor to BrainKey. JDW has received research support from the Alzheimer’s Society, the Royal National Institute for Deaf People, Alzheimer’s Research UK, the National Institute for Health Research University College London Hospitals Biomedical Research Centre and a Frontotemporal Dementia Research Studentship in Memory of David Blechner (funded through The National Brain Appeal). NCF has served as a consultant, on advisory boards, or on a data monitoring committee for Roche, Biogen, Lilly, Eisai and Ionis, and he acknowledges support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetrees Trust, Alzheimer’s Research UK, and the UK Dementia Research Institute. JMS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche Pharmaceuticals, Biogen, Merck, and Eli Lilly; has given educational lectures sponsored by GE Healthcare, Eli Lilly, and Biogen; serves on a Data Safety Monitoring Committee for Axon Neuroscience SE; and is supported by University College London Hospitals Biomedical Research Centre, Engineering and Physical Sciences Research Council (EP/J020990/1), British Heart Foundation (PG/17/90/33415) and EU’s Horizon 2020 Research and Innovation Programme (666992).
Provenance and peer review Not commissioned; externally peer reviewed.